Program

Check back for updates on the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium program.

Designed for clinicians, scientists, and all other members of the cancer care and research community, this three-day meeting focuses on the clinical application of scientific advances in immuno-oncology. At the 2019 Symposium, expert faculty will offer new insights on the application of immunotherapy in lung cancer, genitourinary cancers, melanoma and other skin cancers, breast cancer, and gynecologic cancers. Faculty will also discuss the clinical relevance of immunogenomics, T Cell therapies, cancer vaccines, the microbiome, and promising combination strategies.

Each day of the 2019 program will feature a Keynote Lecture given by world-renowned experts on exciting topics in immuno-oncology including the future of the field and T Cell differentiation and exhaustion.

For members of the cancer care team looking for a foundational understanding of immunology, the Symposium will also feature an early morning “Immunology 201” session.

The meeting will also offer several opportunities for robust networking, discussion, and engagement with faculty members and other attendees. Participants in Networking Roundtable sessions will interact with leaders in the field to discuss research and treatment in all of the disease-sites covered by the educational program. During the Trainee and Early-Career Networking Luncheon, faculty will lead small-group discussions on the clinical application of immuno-oncology specifically tailored for early-career attendees.

7:00 AM-8:25 AM Complimentary Continental Breakfast
7:00 AM-6:30 PM Exhibits Open
8:25 AM-10:00 AM

Welcome and General Session 4: Evolving Role of Immunomodulatory Therapy in Urologic Neoplasms

Robert Dreicer, MD, MS, MACP, FASCO—Chair
University of Virginia

William Y. Kim, MD—Chair
UNC Lineberger Comprehensive Cancer Center

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber/Brigham and Women’s Cancer Center
Welcome

William Y. Kim, MD
UNC Lineberger Comprehensive Cancer Center
Urothelial Cancer: Intersection of Molecular Subtypes and Response to Immuno-Oncology Therapy

Toni K. Choueiri, MD
Dana-Farber Cancer Institute
Next Generation Immuno-Oncology Therapies in Renal Cell Carcinoma

Lawrence Fong, MD
University of California, San Francisco
Does Checkpoint Inhibitor Therapy Have a Role in Prostate Cancer?

 

Abstract 11: Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer. 
First Author: Nicholas Vogelzang, MD, FASCO


Panel Question and Answer

10:00 AM-10:30 AM Break
10:30 AM-11:30 AM General Session 5: Emerging Trends in Cancer Vaccines

Dung T. Le, MD—Chair
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Madhav V. Dhodapkar, MBBS—Chair
Emory University

Anna K. Palucka, MD, PhD
The Jackson Laboratory
Overview and Emerging Approaches for Vaccines

Lana E. Kandalaft, PhD, PharmD
University of Lausanne UNIL/CHUV; Ludwig Cancer Institute Lausanne Branch 
Personalized/Neoantigen Vaccines

Hideho Okada, MD, PhD
University of California, San Francisco
Histone H3.3K27M Mutation–Targeted Immunotherapy for Diffuse Midline Gliomas

Panel Question and Answer
11:30 AM-1:00 PM Poster Session B
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session B
​With Complimentary Boxed Lunch
11:45 AM-12:45 PM

Trainee and Early-Career Networking Luncheon

 

Mario Sznol, MD - Chair
Yale School of Medicine

 

Scott J. Antonia, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute

 

Madhav V. Dhodapkar, MBBS
Emory University

 

Mary L. Disis, MD, FASCO
University of Washington

 

Kim A. Margolin, MD, FASCO
City of Hope

 

Elizabeth A. Mittendorf, MD, PhD
Dana-Farber/Brigham and Women’s Cancer Center

 

Anna K. Palucka, MD, PhD
The Jackson Laboratory

 

Antoni Ribas, MD, PhD
University of California, Los Angeles

1:00 PM-2:15 PM

Oral Abstract Session B

 

Kim A. Margolin, MD, FASCO—Chair
City of Hope

 

Mario Sznol, MD—Chair
Yale School of Medicine

 

Abstract 147: Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice.
First Author: David Pinato, MD, PhD

 

Abstract 130: Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.
First Author: Arnav Mehta, MD, PhD

 

Jason Luke, MD, FACP
University of Chicago Comprehensive Cancer Center
Discussion

 

Abstract 26: Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).
First Author: Adi Diab, MD

 

Abstract 27: Tumor Mutational Burden (TMB): Assessment of inter- and intra-tumor heterogeneity.
First Author: Jeff Conroy

 

Shailender Bhatia, MD
Seattle Cancer Care Alliance
Discussion

 

Panel Question and Answer

2:20 PM-3:00 PM Keynote Lecture

Jedd D. Wolchok, MD, PhD, FASCO
Memorial Sloan Kettering Cancer Center
The Future of Immunotherapy

Panel Question and Answer
3:00 PM-3:30 PM Break
3:30 PM-4:25 PM General Session 6: New Insights in Melanoma and Other Skin Cancers

Mario Sznol, MD—Chair
Yale School of Medicine

Antoni Ribas, MD, PhD—Chair
University of California, Los Angeles

Christian U. Blank, MD, PhD
Netherlands Cancer Institute
Neoadjuvant Therapy for Melanoma and Promising New Immuno-Oncology Combinations With Other Targets

Siwen Hu-Lieskovan, MD, PhD
Huntsman Cancer Institute, University of Utah
Mechanisms of Resistance to Immunotherapy in Melanoma and Strategies to Overcome Them
 

Reinhard Dummer, MD
University of Zurich Hospital
Updates on New Biological Insights and Promising Therapies for Squamous Cell Carcinoma


Panel Question and Answer
4:30 PM-5:30 PM Tumor Board: Toxicity Management and Moderating Case Reports

David B. Miklos, MD, PhD—Chair
Stanford University School of Medicine

Laura S. Wood, MSN, OCN, RN—Chair
Cleveland Clinic Taussig Cancer Institute

Sara M. Tolaney, MD, MPH
Dana-Farber Cancer Institute
Endocrinopathies

Panel Question and Answer

Cassandra Calabrese, DO
Cleveland Clinic
Rheumatologic Immune-Related Adverse Events

Panel Question and Answer

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
Yale University School of Medicine
Multidisciplinary Management

Panel Question and Answer
5:30 PM-6:30 PM Poster Session B
Reception With Complimentary Wine and Cheese
5:30 PM-6:30 PM Trials in Progress Poster Session B
Reception With Complimentary Wine and Cheese
5:45 PM-6:30 PM

Poster Walks

 

Alain Algazi, MD—Poster Walk Leader
University of California, San Francisco

 

Dung T. Le, MD—Poster Walk Leader
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center